New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 25, 2012
09:03 EDTSGENSeattle Genetics completes patients enrollment for clinical trial of ADCETRIS
Seattle Genetics and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company, announced the completion of patient enrollment in a phase III clinical trial of ADCETRIS, or brentuximab vedotin, for post-transplant Hodgkin lymphoma, or HL, patients. The phase III trial, also known as the AETHERA trial, is evaluating ADCETRIS versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL.
News For SGEN From The Last 14 Days
Check below for free stories on SGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
16:31 EDTSGENSeattle Genetics sees FY14 revenue from ADCETRIS $160M-$170M
Subscribe for More Information
16:29 EDTSGENSeattle Genetics reports Q2 EPS (14c), consensus (22c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use